
Heme/Onc Fellow interested in #lungcancer 🫁 @BIDMChealth @DanaFarber @Harvardmed via @OSUWexMed @MUSChealth @UofT | Fan of Cancer Immunology. Views my own
Boston, MA
Joined April 2022
- Tweets169
- Following315
- Followers154
- Likes675
Hyunwoo (Tony) Kwon, MD PhD retweeted
Cancer can silence the molecular alarms that should expose it! Scientists found that loss of CREBBP can epigenetically suppress STING and MHC-I in small-cell lung cancer, helping tumors escape immune detection. A fascinating mechanism of immune invisibility!
doi.org/10.1126/sciadv.aef16…
Hyunwoo (Tony) Kwon, MD PhD retweeted
In #MARIPOSA, amivantamab-lazertinib significantly improved overall survival vs osimertinib. Hayashi et al. found that amivantamab-lazertinib reduces common resistance mechanisms vs osimertinib, suggesting that this regimen is changing the underlying biology of EGFR-mutant disease, contributing to both first- and second-line long-term efficacy outcomes.
Read more here: bit.ly/4z4iFi3
#Amivantamab #Lazertinib #LungCancerResearch
Hyunwoo (Tony) Kwon, MD PhD retweeted
Another reminder @JCOPO_ASCO - early NGS testing in NSCLC before 1L therapy improves outcomes. This retrospective Flatiron study from Drs. @SusanScottMD @benlevylungdoc in > 13k pts showed upfront NGS led to more use of targeted therapy & longer OS.
ascopubs.org/doi/10.1200/PO-…
Hyunwoo (Tony) Kwon, MD PhD retweeted
In the @nytimes, @DanaFarber research, led by Jaclyn LoPiccolo, MD, PhD, links a rare inherited #EGFR mutation to increased lung cancer risk, including never smokers. @DFarberThoracic @DFEGFRcenter
Read more: bit.ly/4rkGlfz
In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients had a response. Full study results: nej.md/4h0GHUW

ALT A graph showing progression-free survival in patients with RAS-mutant and RAS G12–mutant NSCLC who had received previous first- or second-line platinum-based chemotherapy and anti–programmed cell death 1 or anti–programmed cell death ligand 1 therapy but not docetaxel and received 160 to 220 mg of daraxonrasib.
Hyunwoo (Tony) Kwon, MD PhD retweeted
BREAKING: The most controversial article of the year, claiming that early morning immunotherapy works better than in the afternoon, is now retracted.
After reading the responses provided by the authors to the inconsistencies raised in the web, the @NatureMedicine editors no longer have confidence in the integrity of the results. The only prospective evidence that time-of-day matters for immunotherapy is now gone.
nature.com/articles/s41591-0…
To me, this means (at least) two things.
First, it confirms that prudence on this topic was and remains critical. For as inexpensive it may be to give a drug earlier or later in the day, it carries a much more relevant cost: the one of scientific integrity. We owe our patients to make decisions based on solid data. We should not give up this practice too easily, particularly in the presence of several concerning red flags.
Second, this retraction should also prompt a broader reflection on the current state of peer review, in which unpaid reviewers struggle to keep up with a steady rise in submitted papers. Journals need to improve the process by implementing a formal, consistent, in-depth review of each paper by paid professionals. A practice that, in this case, may have avoided a retraction arriving after 22 citations and after inclusion of this study in at least one meta-analysis. And possibly, after some physicians had already changed their practice in IO administration.
For a thoughtful recap of this story, I recommend this well-written new piece in @ScienceMagazine by Laura Agudelo. I’m grateful to Laura for including my perspective in the article.
science.org/content/article/…
What are the key issues that have emerged on the @NatureMedicine time-of-day IO paper?
1. The clinical trial protocol uploaded to Nature was v1 dated Jan 2, 2022; however, the protocol includes references published in 2024. This calls into question when the protocol was written and if/when it was amended.
2. The clinicaltrials.gov record is concerning and calls into question whether the study was actually randomized.
a. In the first record 9/2022, although the study was noted as randomized, the inclusion/exclusion criteria read as though it was a retrospective study, e.g., “First-line patients received immunological monotherapy or immunological combined chemotherapy” as an inclusion criteria and “Lack of clinical diagnosis and treatment information or loss of follow-up” as an exclusion criteria.
b. In the first record, the primary endpoint, sample size, treatment and ECOG criteria do not match what was in the protocol dated Jan 2, 2022.
c. On 3/19/2024, the study was changed from randomized/interventional to an observational case-control study
d. It was not until 3/30/2024 (2 months before end of randomization) that the study was changed to the design described in the manuscript.
3. The OS K-M curve presented at ASCO had errors – i.e., the censor marks do not match the at-risk table. This raises concerns about the integrity of statistical analyses.
4. The shape of the PFS does not match expectations. With a 6-week scan schedule, one would expect a stair-step drop every 6 weeks when patients have their scheduled imaging. Their PFS curve does not – it is smooth. Of note, in an observational study, a PFS curve generally does not have a staircase look because scans are not performed on a regular set schedule.
5. The 95% CI for the lower bound of the median OS in the manuscript is NE. This is not possible as the median was estimated. There are inconsistencies in the p-values in Table 1 (Baseline Characteristics)
Credit to Daniel Brickman, Amanda Nottke and David Swank for creating this list — and to @houndcl for first identifying several of these issues.
Hyunwoo (Tony) Kwon, MD PhD retweeted
The 7-year OS update from CROWN looks a lot like the 2-and 5-year updates. It’s incredible to see this in a population with advanced metastatic NSCLC. Are we curing some of these “incurable” patients or are we just totally suppressing their disease akin to ART in HIV? #ASCO2026
Hyunwoo (Tony) Kwon, MD PhD retweeted
Consensus definition on resectability of stage III NSCLC from @EORTC published @LancetRespirMed. Current consensus is that N3 or bulky N2 is unresectable but multi-station N2 remains potentially resectable. Does not lend itself perfectly to a flowchart given heterogeneity:
Case report on potential role of combination olaparib and osimetinib after progression on osimetinib with platinum chemotherapy in #EGFR #NSCLC with germline BRCA2 #lcsm @BIDThoracicOnc
clinical-lung-cancer.com/art…
Hyunwoo (Tony) Kwon, MD PhD retweeted
【Long-term Survival: Nivo+Ipi+Chemo vs Pembro+Chemo in advanced NSCLC】
🇯🇵 RWD (Japan): Multicenter Retrospective Study
💡Nivo+Ipi+Chemo (NICT) demonstrates superior long-term survival over Pembro+Chemo (PCT) in PD-L1 <1% NSCLC
📚Lung Cancer 2026
lungcancerjournal.info/artic…
🔑Key Results
👥 457 pts with advanced NSCLC treated with NICT or PCT were stratified by PD-L1 (<1% vs ≥1%) with >40 mos follow-up
📈 PD-L1 <1% Cohort: NICT significantly improved OS compared to PCT (Median OS: 47.4 mos vs 16.6 mos; HR 0.50, p=0.007)
🗓 Long-term Benefit: 3-year OS rates in the <1% group favored NICT (51.5% vs 28.2%, p=0.016)
⚖️ PD-L1 ≥1% Cohort: No significant difference in median OS (28.0 vs 28.4 mos) or PFS between regimens
☠️ Safety profiles were comparable (Grade ≥3 TRAEs, discontinuation, and TRD rates), though NICT had higher incidence of skin/pituitary toxicity
Hyunwoo (Tony) Kwon, MD PhD retweeted
#DICIPLE: 4-year 6-month vs continuation Nivo+Ipi in mNSCLC
◼️ PFS: 18.7m vs NR
◼️ OS: 55.5m vs NR
◼️ 18m OS: 80.6% vs 93.8%
◼️ Grade 3-5 irAEs: 54% → 24%
◼️ QoL: 15.5m vs NR (HR=0.36)
🛑 at 6 months = same survival, less toxicity @JTOonline @OncoAlert
pubmed.ncbi.nlm.nih.gov/4169…
Hyunwoo (Tony) Kwon, MD PhD retweeted
First post of #2026 — and the message is clear.
EGFR-mutated NSCLC is no longer about choosing the next drug, but about designing the right strategy.
#NEJM’s latest editorial crystallizes the shift:
from osimertinib monotherapy to biology-driven combinations, informed by resistance mechanisms, toxicity trade-offs, and ctDNA-guided decision making.
FLAURA2 and MARIPOSA confirm it:
earlier intensification can extend survival — but precision in patient selection now defines good oncology.
2026 starts with a new rule in lung cancer care:
strategy > single agent.
🔗 nejm.org/doi/full/10.1056/NE…
#EGFR #NSCLC #ClinicalPractice
Also, appreciate the work by @Larvol for continuously tracking, analyzing, and synthesizing key oncology developments on X.
@PTarantinoMD | @DrChoueiri | @YJanjigianMD | @szusmani | @SuyogCancer | @UroDocAsh | @lungoncdoc | @HHorinouchi | @KoheiShitara | @DrYukselUrun | @Erman_Akkus | @VincentRK | @GIcancerDoc | @dr_yakupergun | @kazuki_nozawa | @MamMa_mimumemo | @StephenVLiu | @chulkimMD | @DrRishabhOnco | @TiansterZhang | @NiuSanford | @ArndtVogel | @CJTsaiMDPhD | @ADesaiMD | @End_myeloma | @tompowles1 | @Kenrickng1 | @AndreaNecchi | @RobertoFerrara_ | @_ShankarSiva | @declangmurphy | @Dr_ElvinaA | @montypal | @pashtoonkasi | @neerajaiims | @helops79 | @GIMedOnc | @PGrivasMDPhD | @RahulBanerjeeMD
Hyunwoo (Tony) Kwon, MD PhD retweeted
Really sad for the patients but super cool for science. PD1+CTLA4 induces hyper-progression in renal medullary carcinoma (yes you read that right)
mPFS 1.4m. Induced IFNg led to hyper-proliferation in tumor cells
Nasty tumor cells!
nature.com/articles/s41467-0…
Hyunwoo (Tony) Kwon, MD PhD retweeted
🚨 New data on seizure prophylaxis in CAR-T!
A new study evaluated whether levetiracetam (LVT) prevents ICANS in patients receiving anti-CD19 CAR-T for LBCL. Using a propensity-matched cohort of 254 patients, the findings were clear:
🧠 No reduction in ICANS with LVT prophylaxis
• Any-grade ICANS: 32.3% vs 37.1% (ns)
• Severe ICANS (G2–4): 15.1% vs 16.1% (ns)
🩸 BUT: LVT was linked to higher early hematotoxicity (ICAHT)
• G2–4 ICAHT: 37.3% → 63.9% (P < .001)
📉 No differences in OS, PFS, or non-relapse mortality.
🔍 Takeaway: Routine LVT prophylaxis does not prevent ICANS and may increase toxicity. More work needed to define if/when it should be used.
ashpublications.org/bloodadv…
#CAR_T #ICANS #Lymphoma #HemOnc #Immunotherapy #CellTherapy
Hyunwoo (Tony) Kwon, MD PhD retweeted
🔥🚨#November is 🫁
#LungCancerAwareness Month.
Lung Cancer Awareness #SavesLives.
Together, WITH #Patients, we keep the #Fight against #LungCancer.
We have made a great #Progress but still have a long way to go. #LCAM25
👇🏼Sharing, like every year, my #AWARENESS #Mnemonic
Hyunwoo (Tony) Kwon, MD PhD retweeted
🚨 50 years of progress in NSCLC, beautifully captured in this JTO review!
jto.org/article/S1556-0864(2…
From the pre-cisplatin era to molecular profiling, targeted therapies, ICI, and advances in screening & supportive care.
Half a century of lessons, half a century of survival — the true golden age of lung cancer research ✨
@OncoAlert #OncoAlertAF @OncoReporte
@myESMO @_SEOM @gecp_org @LungCancerRx @Lung_Cancers
Hyunwoo (Tony) Kwon, MD PhD retweeted
The Chen-Huang Center for EGFR-Mutant Lung Cancers’ webpage was created to offer resources specifically for patients diagnosed with an #EGFR mutation: dana-farber.org/cancer-care/… #LCSM #CancerResearch
Hyunwoo (Tony) Kwon, MD PhD retweeted
💨🧬🫁 The mutagenic forces shaping the genomes of lung cancer in never smokers. #LCSM nature.com/articles/s41586-0…
Hyunwoo (Tony) Kwon, MD PhD retweeted
Clear survival gains in treating lung cancer reflected in this @NEJM article. All pts with lung cancer treated in public hospitals in France show median survival improved from 8.5 months in 2000 to 20.7 months in 2020. No room for nihilism anymore!
evidence.nejm.org/doi/full/1…
Hyunwoo (Tony) Kwon, MD PhD retweeted
Immensely proud of and grateful for this village! We gathered to celebrate intelligence, integrity, curiosity, and compassion. Congratulations to our graduating @BIDMC_HOFellows and thank you to our BIDMC Heme/Onc family. May your stars shine bright always!





























